Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07241416 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

StatusRecruiting
PhasePhase 3
Started2025-12-05
View on ClinicalTrials.gov ↗

Amendment history

2026-05-07
Study Status, Study Design, Contacts/Locations v3
Enrollment increased: 156 → 206 participants
2026-01-28
Study Status v2
Re-verified, no change to tracked fields
2025-12-23
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-12→confirmed 2025-12-05
Study sitesdetails revised at 1 of 1 site
2025-11-17
Original filing
This study aims to compare the efficacy and safety of rezvilutamide with enzalutamide in the treatment of patients with low-volume metastatic hormone sensitive prostate cancer.
Trial Details
NCT Number NCT07241416
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Enrollment 206 participants
Start Date 2025-12-05
Primary Completion 2027-03 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-11